The Europe Body Fluid Collection And Diagnostics Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
Human body fluids are considered as the most adequate source for the clinical makers regarding the diagnosis of diseases. The benefit of body fluid testing is that they are less invasive, affordable, and can help in quick diagnostics.
Apart from this, altered protein expression profile in body fluid shows the conversion of the phycological states and cellular network of the disease or tissues. Therefore, the diagnostics through the body fluid has emerged as an outstanding approach to identify and discover the biomarkers or expose pathological mechanisms for human disease.
The examination of the human body fluid is fundamentally challenging because of its unique characteristics like protein complexity and the large active variety of protein collection, because of the extraordinary enhancement in the process of sample preparation, proteomics technology, and quantitation, with the increased sensitivity and robust experimental design it is now possible to examine body fluid more effectively.
In the United Kingdom people under age of 40 in the UK are being diagnosed with type 2 diabetes, at a faster rate. Also, the obese and overweight citizens in the nation are increasing rapidly. Due to this rising number of obese citizens, there are high chances of the people getting type 2 diabetes, especially among those aged 18 to 39. Almost 8% of the citizen with diabetes have type 1 diabetes and almost 90% of the citizen with diabetes have type 2 diabetes. This increasing number of diabetic patients will rise the growth opportunities for the body fluid collection and diagnostics market.
The Germany market dominated the Europe Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,676.3 million by 2028. The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
Human body fluids are considered as the most adequate source for the clinical makers regarding the diagnosis of diseases. The benefit of body fluid testing is that they are less invasive, affordable, and can help in quick diagnostics.
Apart from this, altered protein expression profile in body fluid shows the conversion of the phycological states and cellular network of the disease or tissues. Therefore, the diagnostics through the body fluid has emerged as an outstanding approach to identify and discover the biomarkers or expose pathological mechanisms for human disease.
The examination of the human body fluid is fundamentally challenging because of its unique characteristics like protein complexity and the large active variety of protein collection, because of the extraordinary enhancement in the process of sample preparation, proteomics technology, and quantitation, with the increased sensitivity and robust experimental design it is now possible to examine body fluid more effectively.
In the United Kingdom people under age of 40 in the UK are being diagnosed with type 2 diabetes, at a faster rate. Also, the obese and overweight citizens in the nation are increasing rapidly. Due to this rising number of obese citizens, there are high chances of the people getting type 2 diabetes, especially among those aged 18 to 39. Almost 8% of the citizen with diabetes have type 1 diabetes and almost 90% of the citizen with diabetes have type 2 diabetes. This increasing number of diabetic patients will rise the growth opportunities for the body fluid collection and diagnostics market.
The Germany market dominated the Europe Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,676.3 million by 2028. The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Kits & Consumables
- Instruments
- Tests/Services
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Fluorescence in situ hybridization (FISH)
- Others
By Sample Type
- Blood
- Urine
- Saliva
- Cerebrospinal Fluid
By Application
- Diagnostics & Monitoring
- Therapeutic Decision Making
- Prognostics & Screening
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Bio-Rad Laboratories, Inc
- Illumina, Inc
- Qiagen N.V
- Johnson & Johnson
- F.Hoffmann-La Roche Ltd
- Laboratory Corporation of America Holdings
- Biocept, Inc
- MDxHealth SA
- Guardant Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Body Fluid Collection And Diagnostics Market, by Product
1.4.2 Europe Body Fluid Collection And Diagnostics Market, by Technology
1.4.3 Europe Body Fluid Collection And Diagnostics Market, by Sample Type
1.4.4 Europe Body Fluid Collection And Diagnostics Market, by Application
1.4.5 Europe Body Fluid Collection And Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2021, Jan - 2022, Sep) Leading Players
Chapter 4. Europe Body Fluid Collection And Diagnostics Market by Product
4.1 Europe Kits & Consumables Market by Country
4.2 Europe Instruments Market by Country
4.3 Europe Tests/Services Market by Country
Chapter 5. Europe Body Fluid Collection And Diagnostics Market by Technology
5.1 Europe Polymerase Chain Reaction (PCR) Market by Country
5.2 Europe Next Generation Sequencing (NGS) Market by Country
5.3 Europe Fluorescence in situ hybridization (FISH) Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Body Fluid Collection And Diagnostics Market by Sample Type
6.1 Europe Blood Market by Country
6.2 Europe Urine Market by Country
6.3 Europe Saliva Market by Country
6.4 Europe Cerebrospinal Fluid Market by Country
Chapter 7. Europe Body Fluid Collection And Diagnostics Market by Application
7.1 Europe Diagnostics & Monitoring Market by Country
7.2 Europe Therapeutic Decision Making Market by Country
7.3 Europe Prognostics & Screening Market by Country
Chapter 8. Europe Body Fluid Collection And Diagnostics Market by Country
8.1 Germany Body Fluid Collection And Diagnostics Market
8.1.1 Germany Body Fluid Collection And Diagnostics Market by Product
8.1.2 Germany Body Fluid Collection And Diagnostics Market by Technology
8.1.3 Germany Body Fluid Collection And Diagnostics Market by Sample Type
8.1.4 Germany Body Fluid Collection And Diagnostics Market by Application
8.2 UK Body Fluid Collection And Diagnostics Market
8.2.1 UK Body Fluid Collection And Diagnostics Market by Product
8.2.2 UK Body Fluid Collection And Diagnostics Market by Technology
8.2.3 UK Body Fluid Collection And Diagnostics Market by Sample Type
8.2.4 UK Body Fluid Collection And Diagnostics Market by Application
8.3 France Body Fluid Collection And Diagnostics Market
8.3.1 France Body Fluid Collection And Diagnostics Market by Product
8.3.2 France Body Fluid Collection And Diagnostics Market by Technology
8.3.3 France Body Fluid Collection And Diagnostics Market by Sample Type
8.3.4 France Body Fluid Collection And Diagnostics Market by Application
8.4 Russia Body Fluid Collection And Diagnostics Market
8.4.1 Russia Body Fluid Collection And Diagnostics Market by Product
8.4.2 Russia Body Fluid Collection And Diagnostics Market by Technology
8.4.3 Russia Body Fluid Collection And Diagnostics Market by Sample Type
8.4.4 Russia Body Fluid Collection And Diagnostics Market by Application
8.5 Spain Body Fluid Collection And Diagnostics Market
8.5.1 Spain Body Fluid Collection And Diagnostics Market by Product
8.5.2 Spain Body Fluid Collection And Diagnostics Market by Technology
8.5.3 Spain Body Fluid Collection And Diagnostics Market by Sample Type
8.5.4 Spain Body Fluid Collection And Diagnostics Market by Application
8.6 Italy Body Fluid Collection And Diagnostics Market
8.6.1 Italy Body Fluid Collection And Diagnostics Market by Product
8.6.2 Italy Body Fluid Collection And Diagnostics Market by Technology
8.6.3 Italy Body Fluid Collection And Diagnostics Market by Sample Type
8.6.4 Italy Body Fluid Collection And Diagnostics Market by Application
8.7 Rest of Europe Body Fluid Collection And Diagnostics Market
8.7.1 Rest of Europe Body Fluid Collection And Diagnostics Market by Product
8.7.2 Rest of Europe Body Fluid Collection And Diagnostics Market by Technology
8.7.3 Rest of Europe Body Fluid Collection And Diagnostics Market by Sample Type
8.7.4 Rest of Europe Body Fluid Collection And Diagnostics Market by Application
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.5.2 Product Launches and Product Expansions:
9.1.5.3 Acquisition and Mergers:
9.2 Guardant Health, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.3 Illumina, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisition and Mergers:
9.4 Qiagen N.V.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisition and Mergers:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.5.5.2 Product Launches and Product Expansions:
9.6 F. Hoffmann-La Roche Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Product Launches and Product Expansions:
9.7 Laboratory Corporation of America Holdings
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental Analysis
9.7.4 Recent strategies and developments:
9.7.4.1 Partnerships, Collaborations, and Agreements:
9.8 Johnson & Johnson
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental &Regional Analysis
9.8.4 Research & Development Expenses
9.9 Biocept, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Product Launches and Product Expansions:
9.10. MDxHealth SA
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- Biocept, Inc.
- MDxHealth SA
- Guardant Health, Inc.
Methodology
LOADING...
